RecruitingPhase 2NCT06005870

Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression

Studying Cerebrotendinous xanthomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Huazhong University of Science and Technology
Principal Investigator
Liling Zhang, M.D, M.D
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Intervention
Zanubrutinib plus RCHOP(drug)
Enrollment
41 enrolled
Eligibility
18-75 years · All sexes
Timeline
20222026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06005870 on ClinicalTrials.gov

Other trials for Cerebrotendinous xanthomatosis

Additional recruiting or active studies for the same condition.

See all trials for Cerebrotendinous xanthomatosis

← Back to all trials